Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.

A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17beta-estradiol system, at three different dosages (25, 50 and 75 mg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss....

Full description

Bibliographic Details
Main Authors: Cooper, C, Stakkestad, J, Radowicki, S, Hardy, P, Pilate, C, Dain, M, Delmas, P
Format: Journal article
Language:English
Published: 1999